A recent study from Cleveland Clinic shows certain genomic biomarkers appear to be as important as standard clinical factors in identifying which patients are candidates for surveillance or treatment at diagnosis.
New evidence shows that men on active surveillance of prostate cancer can safely wait at least five years between surveillance biopsies. Study authors hope new findings increase appeal of disease monitoring and reduce patient and provider anxiety.
Glickman Urological & Kidney Institute’s care paths codify best practices, making it easier for clinicians to consistently deliver cost-effective, evidence-based care.
Using the new 4Kscore test after a positive result from a traditional PSA test can reduce the number of prostate biopsies by 30 to 50 percent while still accurately identifying high-grade cancers.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A specific port configuration for robotic left-side RPLND in clinical stage I testicular cancer provides maximal range of motion for the instruments and facilitates a thorough, safe, minimally invasive dissection.
About half of men diagnosed with prostate cancer have low-risk disease. Here’s the evidence comparing active surveillance to curative therapy in this large group of patients…